Horizon, H3 Biomedicine Partner on Cancer Drug Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

The firms will partner to carry out experiments that seek to identify cancer genome targets. H3 will carry out early target discovery through pre-clinical research, and Horizon will use its drug discovery tools "to run alongside and support [H3's] discovery biology and chemistry assets and capabilities," the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.